Date: 2017-08-28
Type of information: Grant
Company: Apeiron Biologics (Austria)
Investors: European Investment Bank (EIB)
Amount: € 25 million
Funding type: grant
Planned used:
- The financing will support the development of new pharmaceutical products to treat cancer, particularly a rare type affecting children.
Others:
- • On August 28, 2017, the European Investment Bank (EIB) will provide financing of € 25 million to the Austrian biotech company Apeiron Biologics AG (Apeiron). The transaction with Apeiron was made possible by the support of the "European Fund for Strategic Investments" (EFSI). EFSI is the central pillar of the "Investment Plan for Europe", in which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy.
Therapeutic area: Cancer - Oncology
Is general: Yes
